Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib Trial of R21/Matrix-M Malaria Vaccine in African Children
NCT05155579Phase 1Completed
- Sponsor
- University of Oxford
- Start
- May 2022
- Primary completion
- May 2025
- Modality
- Recombinant Protein Vaccines
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of R21/Matrix-M in malaria (9 arms), sponsored by University of Oxford. Primary endpoints: Safety and reactogenicity at 2 years and Immunogenicity at 2 years. Started May 2022; status: completed.
02
Drugs
R21/Matrix-M
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05155579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155579.